Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

Trial Identifier: FBP00004
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: July 2020
Primary Completion Date: September 2021
Study Completion Date: September 2021
Condition: Influenza Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
UNITED STATES, California San Diego, California, UNITED STATES, 92108
UNITED STATES, Florida Melbourne, Florida, UNITED STATES, 32934
UNITED STATES, Florida Orlando, Florida, UNITED STATES, 32806
UNITED STATES, Illinois Peoria, Illinois, UNITED STATES, 61614
UNITED STATES, Maryland Rockville, Maryland, UNITED STATES, 20850